{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-22-000110","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.611337+00:00","generated_at":"2026-06-22T22:08:27.380370+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Axogen appoints Adrian Tyndall to board; founding director Mark Gold retires Dec 13","bullets":["Founding director Dr. Mark Gold resigns effective Dec 13, 2022; no dispute cited.","Dr. Adrian Tyndall appointed to board effective Dec 13; will serve on Quality, Compliance & Portfolio Committee.","Tyndall is Exec VP for Health Affairs & Dean of Morehouse School of Medicine; former UF College of Medicine interim dean.","Tyndall receives standard director compensation: $10k quarterly cash retainer, $1.25k committee retainer, $275k initial option grant vesting over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-22-000110","json":"https://secwatch.observer/filing/0000805928-22-000110.json","markdown":"https://secwatch.observer/filing/0000805928-22-000110.md","text":"https://secwatch.observer/filing/0000805928-22-000110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000110/0000805928-22-000110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000110/axgn-20221025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T22:08:27.380370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbe758478f","claim":"Mark Gold resigned as Director at Axogen, Inc..","evidence_excerpt":"On October 24, 2022, Mark Gold, M.D. notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Quality, Compliance and Portfolio Management Committee, effective as of 3:00 PM EST on Tuesday, December 13, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000110/0000805928-22-000110-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d5d122f744","claim":"Joseph Adrian Tyndall was appointed as Director at Axogen, Inc..","evidence_excerpt":"On October 25 2022, the Company's Board appointed Joseph Adrian Tyndall, M. D. as a new director to fill the vacant directorship on the Board, effective December 13, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000110/0000805928-22-000110-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}